Literature DB >> 10616878

Impairment of BMIPP accumulation at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy.

K Ohtsuki1, H Sugihara, T Kuribayashi, M Nakagawa.   

Abstract

UNLABELLED: Myocardial scintigraphy using 123I-15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) reveals a high incidence of reduced accumulation of the tracer in patients with hypertrophic cardiomyopathy (HCM). This defect is thought to reflect impairment of myocardial fatty acid metabolism. In this study, the distribution of BMIPP defects was characterized and correlated with the clinical features of patients with HCM.
METHODS: Thirty patients with asymmetric septal hypertrophy (ASH) were examined. Regional BMIPP accumulation was evaluated. Each region was normalized to the accumulation in the nonhypertrophic lateral region, which was represented as 100% on each bull's-eye map. The corresponding thallium accumulation for, each region was then used to correct for the partial-volume effect.
RESULTS: BMIPP accumulation was significantly less in the septal portion of the anterior wall (As), the septal portion of the posterior wall (Ps) and the apex than in the lateral segments. BMIPP defects were significantly more frequent in the As, Ps and apical segments (20.0%, 20.0% and 33.3%, respectively) and were present in the As or Ps segments in 8 patients (27%). The patients with BMIPP defects in the As or Ps segments had a more frequent family history of HCM or sudden death and severe cardiac dysfunction.
CONCLUSION: BMIPP defects occur predominantly in the As and Ps segments in some patients with ASH, which is often associated with severe cardiac dysfunction. The distribution of BMIPP defects may contribute to the classification of HCM and the assessment of its severity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10616878

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

Review 1.  The Japanese experience with metabolic imaging in the clinical setting.

Authors:  Nagara Tamaki; Koichi Morita; Yuko Kawai
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

2.  Beware the pitfalls of beauty: High-quality myocardial images with resolution recovery.

Authors:  Kenichi Nakajima; Hiroto Yoneyama; Piotr Slomka
Journal:  J Nucl Cardiol       Date:  2019-04-10       Impact factor: 5.952

3.  Myocardial perfusion abnormality in the area of ventricular septum-free wall junction and cardiovascular events in nonobstructive hypertrophic cardiomyopathy.

Authors:  Satoshi Kaimoto; Tatsuya Kawasaki; Toshiro Kuribayashi; Michiyo Yamano; Shigeyuki Miki; Tadaaki Kamitani; Hiroaki Matsubara
Journal:  Int J Cardiovasc Imaging       Date:  2011-12-21       Impact factor: 2.357

4.  Relation of 99mTc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy.

Authors:  Satoshi Isobe; Satoru Ohshima; Kazumasa Unno; Hideo Izawa; Katsuhiko Kato; Akiko Noda; Akihiro Hirashiki; Toyoaki Murohara
Journal:  J Nucl Cardiol       Date:  2010-07-16       Impact factor: 5.952

Review 5.  Metabolic imaging using SPECT.

Authors:  Junichi Taki; Ichiro Matsunari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

6.  Detection of apical hypertrophic cardiomyopathy; which is the appropriate imaging modality.

Authors:  E E van der Wall; J J Bax; M J Schalij
Journal:  Int J Cardiovasc Imaging       Date:  2008-10       Impact factor: 2.357

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.